Mitomycin C Found Useful for Recurrence Prevention in NMIBC, Suggests Study
Itay: Researchers have found in a new study that a single postoperative dose of Mitomycin C significantly reduces early recurrence of non–muscle-invasive bladder cancer. Mitomycin C (MMC), an intravesical chemotherapy, is widely used in low- and intermediate-risk non–muscle-invasive bladder cancer. It can be administered immediately after tumor resection, as maintenance therapy, or for chemoablation of small recurrent tumors.
A new review published in Future Oncology by Ludovica Cella from Humanitas University and colleagues provides a comprehensive evaluation of how MMC is being used across different clinical settings in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer (NMIBC).
The authors analyzed data from randomized trials and prospective studies to assess the effectiveness of MMC in three key scenarios: a single instillation immediately after transurethral resection of bladder tumor (TURBT), repeated adjuvant instillations, and its use as a non-surgical chemoablative therapy. Their findings reinforce the central role of MMC in reducing tumor recurrence while maintaining a favorable safety profile.
Key Findings:
- Administering Mitomycin C soon after an uncomplicated TURBT procedure significantly reduces the risk of early tumor recurrence, especially in low-risk patients.
- This immediate post-surgical approach is widely used in clinical practice and is backed by strong evidence for preventing early disease relapse.
- In intermediate-risk patients, repeated MMC instillations provide additional therapeutic benefit.
- Adjuvant MMC therapy lowers recurrence rates by დაახლოებით 30–50% compared with surgery alone.
- It also improves recurrence-free survival by around 20–35%.
- Continued treatment through maintenance cycles may further enhance and prolong these benefits when administered consistently.
- MMC demonstrates minimal systemic toxicity, making it a well-tolerated treatment option.
- Compared to alternatives such as Bacillus Calmette-Guérin, MMC is associated with a lower likelihood of adverse side effects in many patients.
The review also explores emerging applications of MMC, including chemoablation, in which the drug is used to treat small recurrent tumors without surgery. This outpatient-based strategy has shown promising response rates in selected patients, offering a less invasive treatment pathway. Additionally, newer delivery methods, such as gel-based formulations designed to prolong drug contact in the bladder, may further enhance treatment outcomes, although long-term data remain limited.
Overall, the findings highlight that MMC remains a reliable and practical treatment option in NMIBC management. Its ability to reduce recurrence, combined with its safety and ease of administration, supports its continued use across different stages of care. The authors emphasize that treatment decisions should be tailored to individual patient risk profiles, while further research is needed to optimize newer therapeutic approaches and long-term strategies.
Reference:
Cella L, Finocchiaro A, Ślusarczyk A, Krajewski W, Caño Velasco J, Subiela JD, Claps F, Grobet-Jeandin E, Del Giudice F, Gallioli A, Laukhtina E, Marcq G, Mari A, Afferi L, Albisinni S, Soria F, Hurle R, Paciotti M, Ferro M, Perdonà S, Mertens LS, Moschini M, Pradere B, Contieri R; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. Future Oncol. 2026 Apr 27:1-9. doi: 10.1080/14796694.2026.2661768. Epub ahead of print. PMID: 42041162.
Next Story